Impact of molecular testing in clinical practice in gynecologic cancers

Marilyn Huang, Tegan Hunter, Brian Slomovitz, Matthew Schlumbrecht

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: With the growing understanding of the molecular and genetic profiles of cancers, targeted treatments are increasingly utilized in personalized cancer care. The objective of this study was to determine how these advances have translated into practice by examining how often molecular profiling of gynecological tumors led to treatment changes. Methods: We identified women with gynecological cancers at our institution who had molecular tumor testing performed from November 2014 to June 2017. Clinicopathologic data were extracted from medical records. We determined (a) if molecular profiling identified actionable targets for which therapy is available, and (b) whether the patient's treatment course changed as a result of molecular profiling. Chi-square, Wilcoxon rank-sum, and Fisher's exact tests were used with a P < 0.05 considered statistically significant. Results: We identified 152 patients with gynecologic cancers who underwent molecular profiling. Of the 152 patients, 116 (76.3%) had actionable mutations identified, with 41 (35.3%) patients having a treatment change. Stratified by cancer type, molecular profiling most frequently identified an actionable target in patients with endometrial cancer (73.6%). Changes in treatment occurred most frequently in patients with endometrial cancer, 22 (56.4%), and ovarian cancers, 16 (39%), as compared to patients with cervical and vulvar cancer (P = 0.02). Of those patients who received a change in treatment, 39 patients (95.1%) received an FDA-approved therapeutic agent, while two patients (4.8%) were enrolled in a clinical trial. Conclusion: Molecular profiling in gynecologic cancers often identified at least one actionable mutation; however, only in a minority of these cases was the course of treatment changed. Further studies are needed to elucidate optimal timing for testing to best utilize actionable information.

Original languageEnglish (US)
Pages (from-to)2013-2019
Number of pages7
JournalCancer Medicine
Volume8
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Neoplasms
Therapeutics
Endometrial Neoplasms
Vulvar Neoplasms
Mutation
Uterine Cervical Neoplasms
Ovarian Neoplasms
Medical Records
Molecular Biology
Clinical Trials

Keywords

  • cervical cancer
  • endometrial cancer
  • gynecologic cancers
  • Next generation sequence
  • ovarian cancer
  • personalized medicine
  • vulvar cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Impact of molecular testing in clinical practice in gynecologic cancers. / Huang, Marilyn; Hunter, Tegan; Slomovitz, Brian; Schlumbrecht, Matthew.

In: Cancer Medicine, Vol. 8, No. 5, 01.05.2019, p. 2013-2019.

Research output: Contribution to journalArticle

Huang, Marilyn ; Hunter, Tegan ; Slomovitz, Brian ; Schlumbrecht, Matthew. / Impact of molecular testing in clinical practice in gynecologic cancers. In: Cancer Medicine. 2019 ; Vol. 8, No. 5. pp. 2013-2019.
@article{9f8998ab0fcd42bfa868b084d3a60f01,
title = "Impact of molecular testing in clinical practice in gynecologic cancers",
abstract = "Background: With the growing understanding of the molecular and genetic profiles of cancers, targeted treatments are increasingly utilized in personalized cancer care. The objective of this study was to determine how these advances have translated into practice by examining how often molecular profiling of gynecological tumors led to treatment changes. Methods: We identified women with gynecological cancers at our institution who had molecular tumor testing performed from November 2014 to June 2017. Clinicopathologic data were extracted from medical records. We determined (a) if molecular profiling identified actionable targets for which therapy is available, and (b) whether the patient's treatment course changed as a result of molecular profiling. Chi-square, Wilcoxon rank-sum, and Fisher's exact tests were used with a P < 0.05 considered statistically significant. Results: We identified 152 patients with gynecologic cancers who underwent molecular profiling. Of the 152 patients, 116 (76.3{\%}) had actionable mutations identified, with 41 (35.3{\%}) patients having a treatment change. Stratified by cancer type, molecular profiling most frequently identified an actionable target in patients with endometrial cancer (73.6{\%}). Changes in treatment occurred most frequently in patients with endometrial cancer, 22 (56.4{\%}), and ovarian cancers, 16 (39{\%}), as compared to patients with cervical and vulvar cancer (P = 0.02). Of those patients who received a change in treatment, 39 patients (95.1{\%}) received an FDA-approved therapeutic agent, while two patients (4.8{\%}) were enrolled in a clinical trial. Conclusion: Molecular profiling in gynecologic cancers often identified at least one actionable mutation; however, only in a minority of these cases was the course of treatment changed. Further studies are needed to elucidate optimal timing for testing to best utilize actionable information.",
keywords = "cervical cancer, endometrial cancer, gynecologic cancers, Next generation sequence, ovarian cancer, personalized medicine, vulvar cancer",
author = "Marilyn Huang and Tegan Hunter and Brian Slomovitz and Matthew Schlumbrecht",
year = "2019",
month = "5",
day = "1",
doi = "10.1002/cam4.2064",
language = "English (US)",
volume = "8",
pages = "2013--2019",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Impact of molecular testing in clinical practice in gynecologic cancers

AU - Huang, Marilyn

AU - Hunter, Tegan

AU - Slomovitz, Brian

AU - Schlumbrecht, Matthew

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: With the growing understanding of the molecular and genetic profiles of cancers, targeted treatments are increasingly utilized in personalized cancer care. The objective of this study was to determine how these advances have translated into practice by examining how often molecular profiling of gynecological tumors led to treatment changes. Methods: We identified women with gynecological cancers at our institution who had molecular tumor testing performed from November 2014 to June 2017. Clinicopathologic data were extracted from medical records. We determined (a) if molecular profiling identified actionable targets for which therapy is available, and (b) whether the patient's treatment course changed as a result of molecular profiling. Chi-square, Wilcoxon rank-sum, and Fisher's exact tests were used with a P < 0.05 considered statistically significant. Results: We identified 152 patients with gynecologic cancers who underwent molecular profiling. Of the 152 patients, 116 (76.3%) had actionable mutations identified, with 41 (35.3%) patients having a treatment change. Stratified by cancer type, molecular profiling most frequently identified an actionable target in patients with endometrial cancer (73.6%). Changes in treatment occurred most frequently in patients with endometrial cancer, 22 (56.4%), and ovarian cancers, 16 (39%), as compared to patients with cervical and vulvar cancer (P = 0.02). Of those patients who received a change in treatment, 39 patients (95.1%) received an FDA-approved therapeutic agent, while two patients (4.8%) were enrolled in a clinical trial. Conclusion: Molecular profiling in gynecologic cancers often identified at least one actionable mutation; however, only in a minority of these cases was the course of treatment changed. Further studies are needed to elucidate optimal timing for testing to best utilize actionable information.

AB - Background: With the growing understanding of the molecular and genetic profiles of cancers, targeted treatments are increasingly utilized in personalized cancer care. The objective of this study was to determine how these advances have translated into practice by examining how often molecular profiling of gynecological tumors led to treatment changes. Methods: We identified women with gynecological cancers at our institution who had molecular tumor testing performed from November 2014 to June 2017. Clinicopathologic data were extracted from medical records. We determined (a) if molecular profiling identified actionable targets for which therapy is available, and (b) whether the patient's treatment course changed as a result of molecular profiling. Chi-square, Wilcoxon rank-sum, and Fisher's exact tests were used with a P < 0.05 considered statistically significant. Results: We identified 152 patients with gynecologic cancers who underwent molecular profiling. Of the 152 patients, 116 (76.3%) had actionable mutations identified, with 41 (35.3%) patients having a treatment change. Stratified by cancer type, molecular profiling most frequently identified an actionable target in patients with endometrial cancer (73.6%). Changes in treatment occurred most frequently in patients with endometrial cancer, 22 (56.4%), and ovarian cancers, 16 (39%), as compared to patients with cervical and vulvar cancer (P = 0.02). Of those patients who received a change in treatment, 39 patients (95.1%) received an FDA-approved therapeutic agent, while two patients (4.8%) were enrolled in a clinical trial. Conclusion: Molecular profiling in gynecologic cancers often identified at least one actionable mutation; however, only in a minority of these cases was the course of treatment changed. Further studies are needed to elucidate optimal timing for testing to best utilize actionable information.

KW - cervical cancer

KW - endometrial cancer

KW - gynecologic cancers

KW - Next generation sequence

KW - ovarian cancer

KW - personalized medicine

KW - vulvar cancer

UR - http://www.scopus.com/inward/record.url?scp=85066398107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066398107&partnerID=8YFLogxK

U2 - 10.1002/cam4.2064

DO - 10.1002/cam4.2064

M3 - Article

C2 - 30848097

AN - SCOPUS:85066398107

VL - 8

SP - 2013

EP - 2019

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 5

ER -